Corporative

Repurposing drugs; more than $20Billion in sales

September, 2012

A recent Thomson Reuters report indicates that drug repositioning is expected to generate up to $20Billion in annual sales during 2012, thus opening up a new source of revenue to large, medium and small Pharma companies.

SOM Biotech in New European Economy

Winter, 2012

SOM Biotech, has been identified as one of the best opportunities to invest in start-up biopharmaceuticals companies in Catalonia. Link: http://www.neweuropeaneconomy.com/home-mainmenu-51/fdi-mainmenu-59/514-adding-value-to-existing-drugs

SOM0226 presented at the XIIIth International Symposium on Amyloidosis

May 6^th-10^th, 2012

SOM0226, a reprofiled drug for the treatment of TTR amyloidosis, has been presented at the XIII^th International Symposium on Amyloidosis in Groningen, The Netherlands. The product has been recognized as one of the most promising in-coming therapies by the scientific expert community in the field.

SOM Biotech granted SME status by the EMA

Apr 17^th, 2012

SOM Biotech has been granted SME status as micro-sized enterprise in research and development by the European Medicine Agency (EMA). The main incentives include: fee reductions in regulatory procedures and scientific advice, administrative assistance, and more economical access to various services provided by EMA.

SOM Biotech starts collaborations with Aagami Inc.

Mar 15^th, 2012

SOM Biotech reaches an agreement with Aagami Inc. to start collaborations with Indian pharmaceutical companies interested in drug reprofiling.

More Articles...